Tango Therapeutics, Inc.

NasdaqGM:TNGX 주식 리포트

시가총액: US$4.5b

Tango Therapeutics 경영진

경영진 기준 점검 2/4

Tango Therapeutics CEO는 Malte Peters, Jan2026 에 임명되었습니다 의 임기는 1년 미만입니다. 는 $348.07K 가치에 해당하는 회사 주식의 0.008% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 각각 0.4 년과 5.3 년입니다.

핵심 정보

Malte Peters

최고경영자

US$1.2m

총 보수

CEO 급여 비율n/a
CEO 재임 기간less than a year
CEO 지분 보유율0.008%
경영진 평균 재임 기간less than a year
이사회 평균 재임 기간5.3yrs

최근 경영진 업데이트

Recent updates

Seeking Alpha • 12h

Tango Therapeutics: Combo Data With Revolution's RAS Inhibitor Whets Risk Appetite

Summary Tango Therapeutics, Inc. surged over 625% since January 2025, driven by best-in-class Phase 1/2 data for vopimetostat in combination with RAS inhibitors. Vopimetostat plus daraxonrasib achieved a 92% objective response rate in MTAP-deleted, RAS-mutant metastatic pancreatic cancer, supporting rapid advancement to Phase 3. TNGX is now exclusively focused on PRMT5 inhibitors, with robust funding—$380M cash plus a $500M equity raise—supporting operations into 2028. I maintain a Hold rating for TNGX, citing the need for clarity on Tango’s and Revolution’s strategic paths, upcoming monotherapy data, and potential M&A interest. Read the full article on Seeking Alpha
분석 기사 • Jan 19

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 53% Price Boost Is Out Of Tune With Revenues

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shareholders have had their patience rewarded with a 53% share price jump in...
분석 기사 • Dec 05

Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 32%

Despite an already strong run, Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares have been powering on, with a gain of...
분석 기사 • Sep 17

Tango Therapeutics, Inc. (NASDAQ:TNGX) Investors Are Less Pessimistic Than Expected

With a price-to-sales (or "P/S") ratio of 33.7x Tango Therapeutics, Inc. ( NASDAQ:TNGX ) may be sending very bearish...
분석 기사 • May 15

US$10.43: That's What Analysts Think Tango Therapeutics, Inc. (NASDAQ:TNGX) Is Worth After Its Latest Results

The analysts might have been a bit too bullish on Tango Therapeutics, Inc. ( NASDAQ:TNGX ), given that the company fell...
분석 기사 • Apr 14

Little Excitement Around Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Revenues As Shares Take 28% Pounding

Unfortunately for some shareholders, the Tango Therapeutics, Inc. ( NASDAQ:TNGX ) share price has dived 28% in the last...
분석 기사 • Apr 04

Here's Why We're Watching Tango Therapeutics' (NASDAQ:TNGX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
분석 기사 • Feb 28

Tango Therapeutics, Inc. (NASDAQ:TNGX) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough

To the annoyance of some shareholders, Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares are down a considerable 30% in...
분석 기사 • Feb 28

Tango Therapeutics, Inc. (NASDAQ:TNGX) Not Doing Enough For Some Investors As Its Shares Slump 30%

To the annoyance of some shareholders, Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares are down a considerable 30% in...
Seeking Alpha • Jan 23

Tango Therapeutics: Chance For A Short Squeeze

Summary Tango Therapeutics is a growing cancer drug development company with partners such as Gilead Sciences. Given the high short interest and the low number of shares outstanding, I expect a short squeeze to occur, which could lead to an increase in TNGX's share price thereafter. Despite the negative sentiment, recent institutional selling and call option activity suggest potential value accumulation and positive momentum for TNGX. I decided to buy OTM call options on TNGX due to the low implied volatility. Read the full article on Seeking Alpha
분석 기사 • Dec 05

Is Tango Therapeutics (NASDAQ:TNGX) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Oct 31

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Unfortunately for some shareholders, the Tango Therapeutics, Inc. ( NASDAQ:TNGX ) share price has dived 26% in the last...
Seeking Alpha • Sep 10

Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data

Summary Tango Therapeutics, Inc. offers high-risk, high-reward exposure to PRMT5-inhibitor drugs, with two candidates, TNG908 and TNG462, targeting MTAP-deleted cancers, a substantial market opportunity. TNGX stock volatility is influenced by competitors' PRMT5 data, with recent fluctuations driven by Amgen and Mirati's clinical results. Tango's financial stability is supported by >$300M in cash, a Gilead partnership, and a funding runway until 2027, covering key clinical readouts. Despite the high risk, Tango's differentiated approach and potential blockbuster candidates make TNGX stock an intriguing speculative buy ahead of critical data readouts. Read the full article on Seeking Alpha
분석 기사 • Sep 01

What Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 29% Share Price Gain Is Not Telling You

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares have continued their recent momentum with a 29% gain in the last month...
분석 기사 • Jun 29

Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 27%

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares have had a really impressive month, gaining 27% after a shaky period...
분석 기사 • May 30

Shareholders May Not Be So Generous With Tango Therapeutics, Inc.'s (NASDAQ:TNGX) CEO Compensation And Here's Why

Key Insights Tango Therapeutics will host its Annual General Meeting on 5th of June Salary of US$626.0k is part of CEO...
분석 기사 • Mar 19

Risks Still Elevated At These Prices As Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Dive 30%

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares have had a horrible month, losing 30% after a relatively good period...
분석 기사 • Mar 06

Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Tango Therapeutics...
분석 기사 • Jan 08

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Share Price Could Signal Some Risk

You may think that with a price-to-sales (or "P/S") ratio of 25x Tango Therapeutics, Inc. ( NASDAQ:TNGX ) is a stock to...
분석 기사 • Nov 09

Industry Analysts Just Upgraded Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts By 15%

Shareholders in Tango Therapeutics, Inc. ( NASDAQ:TNGX ) may be thrilled to learn that the analysts have just delivered...
분석 기사 • Aug 12

New Forecasts: Here's What Analysts Think The Future Holds For Tango Therapeutics, Inc. (NASDAQ:TNGX)

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shareholders will have a reason to smile today, with the analysts making...
분석 기사 • May 10

Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Oct 20

Tango Therapeutics started at buy at Wainwright on synthetically lethal targets for cancer

H.C. Wainwright has started Tango Therapeutics (NASDAQ:TNGX) with a buy rating citing its use of synthetic lethality to develop cancer candidates. The firm has a $10 price target (~43% upside based on Wednesday's close). Analyst Robert Burns said that the targets the company is focused on could potentially treat large patient populations. He cited TNG908, Tango's (TNGX) most advanced candidate, currently in phase 1/2 for MTAP-deleted tumors. Initial data is expected in H1 2023. After determining the optimum dose for TNG908, Tango (TNGX) says it will evaluate efficacy in multiple tumor types in specific cohorts, including malignant peripheral nerve sheath tumor, non-small cell lung cancer, mesothelioma, cholangiocarcinoma, and glioblastoma. Seeking Alpha's Quant Rating views Tango (TNGX) as a buy with high marks for growth and momentum.
분석 기사 • Oct 05

Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
분석 기사 • Aug 13

Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

The investors in Tango Therapeutics, Inc. 's ( NASDAQ:TNGX ) will be rubbing their hands together with glee today...
Seeking Alpha • Aug 10

Tango Therapeutics GAAP EPS of -$0.28 beats by $0.03, revenue of $5.78M beats by $0.12M

Tango Therapeutics press release (NASDAQ:TNGX): Q2 GAAP EPS of -$0.28 beats by $0.03. Revenue of $5.78M (-68.2% Y/Y) beats by $0.12M.
분석 기사 • May 28

We're Not Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

CEO

Malte Peters (64 yo)

less than a year
재임 기간
US$1,151,381
보수

Dr. Malte Peters, MD., is Director at HOOKIPA Pharma Inc. since 2023 and is its Chief Executive Officer since July 22, 2024 and served as its Ad Interim Senior Clinical Advisor from September 2023 until Ma...

리더십 팀

이름직위재임 기간보수지분
Barbara Weber
Founder & Executive Chairman of the Board9.3yrsUS$2.82m1.07%
$ 48.0m
Malte Peters
Presidentless than a yearUS$1.15m0.0078%
$ 348.1k
Daniella Beckman
Executive Officerless than a yearUS$1.16m0.091%
$ 4.1m
Adam Crystal
President of Research & Development3.3yrsUS$1.72m0.012%
$ 532.8k
Alan Ashworth
Founder & Member of Scientific Advisory Boardno data데이터 없음데이터 없음
William Kaelin
Founder & Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Antoni Ribas
Founder & Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Matthew Gall
Chief Financial Officerless than a year데이터 없음데이터 없음
Jannik Andersen
Chief Scientific Officer2.7yrs데이터 없음데이터 없음
Julie Fogarty
Vice President of Legal & Corporate Secretaryno data데이터 없음데이터 없음
Julie Carretero
Chief Human Resources Officer2.3yrs데이터 없음데이터 없음
Philippe Serrano
Chief Regulatory Officerless than a year데이터 없음데이터 없음
0.4yrs
평균 재임 기간
59yo
평균 나이

경험이 풍부한 관리: TNGX의 경영진은 경험이 부족한 것으로 간주됩니다(평균 재임 0.4 년) — 신규 팀일 수 있습니다.

이사회 구성원

이름직위재임 기간보수지분
Barbara Weber
Founder & Executive Chairman of the Board9.3yrsUS$2.82m1.07%
$ 48.0m
Malte Peters
President7.8yrsUS$1.15m0.0078%
$ 348.1k
Alan Ashworth
Founder & Member of Scientific Advisory Board5.4yrs데이터 없음데이터 없음
William Kaelin
Founder & Member of Scientific Advisory Board5.4yrs데이터 없음데이터 없음
Antoni Ribas
Founder & Member of Scientific Advisory Board5.4yrs데이터 없음데이터 없음
Mace Rothenberg
Independent Director5.3yrsUS$169.70k0.0078%
$ 348.1k
Lesley Calhoun
Independent Director5.3yrsUS$176.33k0.0043%
$ 193.3k
John Ketchum
Independent Director2.8yrsUS$196.14k0.0078%
$ 351.2k
Sung Lee
Lead Independent Directorless than a year데이터 없음0%
$ 0
Alan Huang
Member of Scientific Advisory Board1.4yrsUS$1.88m데이터 없음
5.3yrs
평균 재임 기간
64.5yo
평균 나이

경험이 풍부한 이사회: TNGX의 이사회는 경험이 있음으로 간주됩니다(평균 재임 5.3 년).

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/06/09 07:39
종가2026/06/09 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Tango Therapeutics, Inc.는 14명의 분석가가 다루고 있습니다. 이 중 10명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Yuan ZhiB. Riley Securities, Inc.
John NewmanCanaccord Genuity
Eric SchmidtCantor Fitzgerald & Co.